Free Trial

QuidelOrtho (QDEL) Competitors

$42.40
+0.55 (+1.31%)
(As of 05/24/2024 ET)

QDEL vs. NEOG, CLDX, NTLA, MYGN, LNTH, ENOV, AZTA, MRVI, MOR, and RNA

Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Enovis (ENOV), Azenta (AZTA), Maravai LifeSciences (MRVI), MorphoSys (MOR), and Avidity Biosciences (RNA). These companies are all part of the "medical" sector.

QuidelOrtho vs.

Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.7% of Neogen shares are owned by company insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neogen presently has a consensus target price of $22.50, indicating a potential upside of 69.68%. QuidelOrtho has a consensus target price of $59.00, indicating a potential upside of 39.15%. Given QuidelOrtho's stronger consensus rating and higher probable upside, research analysts plainly believe Neogen is more favorable than QuidelOrtho.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neogen
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
QuidelOrtho
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$822.45M3.49-$22.87M$0.011,327.33
QuidelOrtho$3.00B0.95-$10.10M-$26.39-1.61

QuidelOrtho received 110 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.28% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.

CompanyUnderperformOutperform
NeogenOutperform Votes
330
57.19%
Underperform Votes
247
42.81%
QuidelOrthoOutperform Votes
440
67.28%
Underperform Votes
214
32.72%

Neogen has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

In the previous week, QuidelOrtho had 10 more articles in the media than Neogen. MarketBeat recorded 12 mentions for QuidelOrtho and 2 mentions for Neogen. QuidelOrtho's average media sentiment score of 1.73 beat Neogen's score of 0.20 indicating that Neogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neogen
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
QuidelOrtho
4 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neogen has a net margin of 0.17% compared to Neogen's net margin of -61.65%. Neogen's return on equity of 3.96% beat QuidelOrtho's return on equity.

Company Net Margins Return on Equity Return on Assets
Neogen0.17% 3.35% 2.30%
QuidelOrtho -61.65%3.96%2.24%

Summary

Neogen and QuidelOrtho tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QDEL vs. The Competition

MetricQuidelOrthoDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$2.84B$3.29B$5.20B$8.06B
Dividend YieldN/A0.70%2.83%3.93%
P/E Ratio-1.61154.36152.1518.19
Price / Sales0.9577.302,464.4379.80
Price / Cash3.8717.0136.3031.61
Price / Book0.863.695.444.60
Net Income-$10.10M$32.98M$106.24M$214.07M
7 Day Performance-0.98%-2.90%-1.33%-1.08%
1 Month Performance3.87%2.27%2.76%3.20%
1 Year Performance-51.21%-27.56%3.39%7.84%

QuidelOrtho Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEOG
Neogen
2.9159 of 5 stars
$13.37
-2.2%
$22.50
+68.3%
-22.0%$2.90B$822.45M1,338.342,640Positive News
CLDX
Celldex Therapeutics
0.9261 of 5 stars
$37.67
-0.2%
$66.00
+75.2%
+15.3%$2.48B$6.88M-13.22160
NTLA
Intellia Therapeutics
3.462 of 5 stars
$25.71
-0.7%
$66.77
+159.7%
-40.5%$2.48B$36.28M-4.80526Positive News
MYGN
Myriad Genetics
2.6942 of 5 stars
$24.38
-2.5%
$25.57
+4.9%
+1.0%$2.21B$753.20M-8.652,700
LNTH
Lantheus
4.421 of 5 stars
$80.70
-2.6%
$99.17
+22.9%
-18.8%$5.59B$1.30B12.32834Positive News
ENOV
Enovis
2.975 of 5 stars
$50.39
-1.5%
$75.43
+49.7%
-6.6%$2.76B$1.82B-33.596,550
AZTA
Azenta
2.4228 of 5 stars
$51.55
+0.1%
$68.40
+32.7%
+22.2%$2.78B$665.07M-19.023,500
MRVI
Maravai LifeSciences
2.4112 of 5 stars
$10.95
-3.4%
$11.44
+4.5%
-19.0%$2.75B$288.95M-11.06650Positive News
MOR
MorphoSys
0.6085 of 5 stars
$18.51
-0.2%
$11.78
-36.4%
+195.7%$2.79B$257.89M-5.32524
RNA
Avidity Biosciences
1.1178 of 5 stars
$29.51
+0.9%
$38.29
+29.7%
+142.7%$2.82B$9.56M-10.00253Insider Selling

Related Companies and Tools

This page (NASDAQ:QDEL) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners